Knight Therapeutics Inc. Acquires Orphan Canada Inc. and Expands Business Development Capacity - Seite 2

About PHOTOFRIN®

Photodynamic therapy with PHOTOFRIN® is a two-stage process requiring administration of both drug and light. The first stage of PDT is the intravenous injection of PHOTOFRIN®. The second stage of therapy uses illumination with nonburning laser light 40-50 hours following injection with PHOTOFRIN®. When injected, PHOTOFRIN® is attracted to certain tissues, especially cancer cells. Tumor destruction results from biochemical reactions, not heat. Tumor selectivity occurs through a combination of preferential retention of PHOTOFRIN® by the tumor and selective delivery of light to the tumor site. PHOTOFRIN® is indicated for the treatment of esophageal cancer, non-small-cell lung cancer and high-grade dysplasia in Barrett's esophagus in both the U.S. and Canada. PHOTOFRIN® was granted orphan drug designation (ODD) by the FDA in October 2001 for the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy, in November 2004 for cholangiocarcinoma (CCA), a rare cancer in the bile ducts that carry bile from the liver to the small intestine, and in December 2011, as adjuvant therapy to surgery for the treatment of malignant pleural mesothelioma.

About ATryn®

ATryn® is a recombinant antithrombin indicated for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients. It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients. ATryn® received FDA approval in 2009 and marketing authorization by the European Commission prior to that in 2006. ATryn® will be submitted shortly for approval to Health Canada.

About Jason Flowerday

Jason Flowerday is a respected healthcare executive and entrepreneur with two decades of experience in the pharma/biotech and marketing services industries. Jason, along with his business partner, Joost van der Mark, founded Orphan Canada in 2010 (formerly GARD Therapeutics). Prior to Orphan Canada, Jason established RxMedia Healthcare Communications in 2006, leading the company through a six-year period of sustained growth and expansion. Jason successfully sold RxMedia in 2012. From 1995 to 2005, Jason held a succession of commercial positions at Bayer Healthcare that culminated in Jason serving as the Director of Marketing for Bayer's Anti-Infectives portfolio. Following ten rewarding years at Bayer, Jason joined Ortho Biotech where he led the Nephrology Business unit as the Marketing Director for two years. Jason holds an Honours B.Sc. from the University of Toronto and an M.B.A. from Queen's School of Business.